Curtis Mello, MD
Pulmonary Disease · North Dartmouth, MANPI 1124080312
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 62.6% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $39,972 and has fallen 85.1% since, to $5,952 in 2025. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 376 payments — averaging $262.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$62K
- Mylan Specialty L.p.$13K
- AstraZeneca$10K
- Ensodata, Inc.$5K
- Chiesi USA, Inc.$4K
- Viatris Specialty LLC$3K
- plus $2K from 19 others
Across 584 payments — averaging $3027.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$402K
- Sanofi US Services Inc.$295K
- GSK$283K
- Daiichi Sankyo Inc.$195K
- Boehringer Ingelheim$116K
- Novo Nordisk AS$107K
- plus $371K from 10 others
What the payments were for
- Consulting fees$27,29028%
- Speaking & faculty fees$54,38255%
- Travel & lodging$9,2899%
- Food & beverage$7,6168%
- Education$1890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 105 | $61,810 |
| Mylan Specialty L.p. | 26 | $13,360 |
| AstraZeneca | 136 | $9,512 |
| Ensodata, Inc. | 1 | $5,000 |
| Chiesi USA, Inc. | 4 | $3,977 |
| Viatris Specialty LLC | 5 | $3,037 |
| GSK | 55 | $891 |
| Amgen | 11 | $245 |
| Sanofi | 5 | $142 |
| Harmony Biosciences LLC | 6 | $136 |
| Inspire Medical Systems, Inc. | 2 | $125 |
| Insmed, Inc. | 1 | $100 |
| Regeneron Healthcare Solutions, Inc. | 3 | $79 |
| Pfizer | 3 | $66 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Verona Pharma, Inc. | 1 | $34 |
| Actelion Pharmaceuticals US, Inc. | 1 | $33 |
| Jazz Pharmaceuticals Inc. | 1 | $33 |
| Merck | 1 | $26 |
| Novartis | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| 3b Medical, Inc. | 1 | $21 |
| Electromed, Inc. | 2 | $20 |
| Phadia US Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPIRIVA$19,846
- Yupelri$16,031
- STIOLTO RESPIMAT$6,841
- FASENRA$6,600
- SPIRIVA RESPIMAT$1,345
- NUCALA$122
How this compares
$98,765 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 32 | $409,268 |
| XywavSodium,calcium,mag,pot Oxybate | 19 | $313,686 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 326 | $237,356 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 217 | $151,465 |
| Dupixent SyringeDupilumab | 27 | $107,283 |
| Breo ElliptaFluticasone/Vilanterol | 238 | $104,058 |
| Spiriva RespimatTiotropium Bromide | 120 | $77,122 |
| Dupixent PenDupilumab | 16 | $61,059 |
| SymbicortBudesonide/Formoterol Fumarate | 206 | $59,529 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 101 | $57,846 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 111 | $56,346 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 150 | $42,596 |
| EliquisApixaban | 54 | $35,192 |
| Arnuity ElliptaFluticasone Furoate | 116 | $32,649 |
| DuleraMometasone/Formoterol | 66 | $31,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $61,810 | $555,805272 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $891 | $453,297842 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Pulmicort Flexhaler | $9,512 | $229,794466 claims |
| MerckDulera, Januvia | $26 | $38,50490 claims |
| PfizerEliquis | $66 | $35,19254 claims |
| Novo NordiskOzempic | $22 | $28,02916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in North Dartmouth
- Christos KapogiannisNorth Dartmouth$65K
- Yaron GoldmanWorcester$843K
- Sarah GrantBrookline$678K
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Fernando MartinezWorcester$375K
- Ana CojocaruFall River$364K
- Adnan MajidBoston$351K
- Adam SmithBurlington$296K
- Nicholas HillBoston$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.